Skip to main content

Press Releases

Date Title
Toggle Summary Sienna Biopharmaceuticals Establishes Corporate Advisory Board
Diverse Panel of Key Opinion Leaders to Share Expertise Across Company’s Therapeutic Focus Areas WESTLAKE VILLAGE, Calif. , Dec. 12, 2017 (GLOBE NEWSWIRE) -- Sienna Biopharmaceuticals, Inc. (NASDAQ:SNNA) today announced the formation of a Corporate Advisory Board that will provide scientific,
Toggle Summary Sienna Biopharmaceuticals to Present at BMO Capital Markets Healthcare Conference
WESTLAKE VILLAGE, Calif. , Dec. 11, 2017 (GLOBE NEWSWIRE) -- Sienna Biopharmaceuticals, Inc. (NASDAQ:SNNA) today announced that Frederick C. Beddingfield III , M.D., Ph.D., President and Chief Executive Officer of Sienna, is scheduled to participate in a fireside chat at the BMO Capital Markets
Toggle Summary Sienna Biopharmaceuticals Reports Third Quarter 2017 Financial Results
WESTLAKE VILLAGE, Calif. , Nov. 09, 2017 (GLOBE NEWSWIRE) -- Sienna Biopharmaceuticals, Inc. (NASDAQ:SNNA) today reported the Company’s financial results for the third quarter of 2017. “We are pleased to report the results of our third quarter,” said Frederick C.
Toggle Summary Sienna Biopharmaceuticals Announces First Patient Dosed in Phase 2b Trial of Topical SNA-120
-- Trial to Enroll Approximately 190 Patients with Pruritus Associated with Psoriasis -- Top-Line Results Expected in First Half of 2019 WESTLAKE VILLAGE, Calif. , Oct. 24, 2017 (GLOBE NEWSWIRE) -- Sienna Biopharmaceuticals, Inc. (NASDAQ:SNNA) today announced that the first patient has been dosed

SEC Filings

Events

Date Title
Summary Toggle Dec 14, 2017 at 11:00 AM EST

Stock Information

Copyright Nasdaq. Minimum 15 minutes delayed.

Refresh quote

Analyst Coverage

Firm Analyst
J.P. Morgan
Chris Schott
Cowen
Ken Cacciatore
BMO Capital Markets
Gary Nachman
Guggenheim Securities
Rohit Vanjani

The analysts above have initiated and are maintaining formal research coverage of Sienna. Please note that any opinions, estimates or forecasts regarding Sienna’s performance made by these analysts are theirs alone and do not represent opinions, forecasts or predictions of Sienna or Sienna’s management. Sienna does not by reference above or distribution of same imply endorsement of or concurrence with any analyst’s opinions, estimates, forecasts, conclusions or recommendations. Sienna does not participate in the preparation of analysts’ reports and undertakes no obligation to verify or correct any information in such reports.

Transfer Agent

Wells Fargo Shareowner Services
www.shareowneronline.com

IR Contact

IR@SiennaBio.com

Media Contact

media@SiennaBio.com